Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Experimental RNAi02:15

Experimental RNAi

6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
RNA Editing02:23

RNA Editing

9.1K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.1K
Types of RNA01:20

Types of RNA

5.9K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
5.9K
RNA Interference01:23

RNA Interference

26.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of Gene Expression by N<sup>6</sup>-methyladenosine in Cancer.

Trends in cell biology·2019
Same author

Molecular mechanisms of atomic layer etching of cobalt with sequential exposure to molecular chlorine and diketones.

Journal of vacuum science & technology. A, Vacuum, surfaces, and films : an official journal of the American Vacuum Society·2019
Same author

miR‑146a‑5p expression is upregulated by the CXCR4 antagonist TN14003 and attenuates SDF‑1‑induced cartilage degradation.

Molecular medicine reports·2019
Same author

Author Correction: Anti-tumour immunity controlled through mRNA m<sup>6</sup>A methylation and YTHDF1 in dendritic cells.

Nature·2019
Same author

Total Syntheses of (+)-Sarcophytin, (+)-Chatancin, (-)-3-Oxochatancin, and (-)-Pavidolide B: A Divergent Approach.

Angewandte Chemie (International ed. in English)·2019
Same author

Histone H3 trimethylation at lysine 36 guides m<sup>6</sup>A RNA modification co-transcriptionally.

Nature·2019

Related Experiment Video

Updated: Jul 31, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

497

Advances in targeting RNA modifications for anticancer therapy.

Monica M Pomaville1, Chuan He2

  • 1Department of Pediatrics, University of Chicago Comer Children's Hospital, Chicago, IL, USA; Howard Hughes Medical Institute, University of Chicago, Chicago, IL, USA; Department of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, University of Chicago, Chicago, IL, USA.

Trends in Cancer
|May 5, 2023
PubMed
Summary
This summary is machine-generated.

Cancer cells utilize RNA modifications like N-methyladenosine (m6A) for gene regulation and tumor growth. Targeting m6A proteins offers a promising therapeutic strategy for cancer treatment.

Keywords:
METTL3N(6)-methyladenosineRNA modificationscancerepitranscriptomics

More Related Videos

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.6K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.7K

Related Experiment Videos

Last Updated: Jul 31, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

497
Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.6K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.7K

Area of Science:

  • Epitranscriptomics
  • Cancer Biology
  • Molecular Oncology

Background:

  • Cancer cells employ diverse gene expression strategies for tumorigenesis.
  • RNA modifications, particularly N-methyladenosine (m6A), are emerging as key regulators in disease.
  • Aberrant m6A placement in cancer influences gene expression and immune response.

Purpose of the Study:

  • To investigate the role of m6A RNA modifications in cancer development.
  • To explore m6A writer, reader, and eraser proteins as potential therapeutic targets.
  • To highlight the significance of epitranscriptomics in oncology.

Main Methods:

  • Review of preclinical evidence on m6A modification pathways.
  • Analysis of m6A reader proteins' function in RNA fate determination.
  • Examination of ongoing first-in-human studies targeting METTL3/METTL14 complex.

Main Results:

  • m6A modification is prevalent in mammalian mRNA and dysregulated in cancer.
  • m6A-modified RNA can promote tumorigenesis by altering gene expression and immune surveillance.
  • m6A writer, reader, and eraser proteins are validated as potential therapeutic targets.

Conclusions:

  • Epitranscriptomic modifications, especially m6A, play a critical role in cancer progression.
  • Targeting the m6A machinery, including the METTL3/METTL14 complex, shows therapeutic potential.
  • Further investigation into RNA modifications is crucial for developing novel cancer treatments.